Ironwood Stock Analysis

IRWD -  USA Stock  

USD 11.09  0.05  0.45%

The latest Ironwood Pharmaceuti price dip may raise some interest from shareholders. The stock closed today at a share price of 11.09 on 58,444 in trading volume. The company executives were unable to exploit market volatilities in December. However, diversifying your overall positions with Ironwood Pharmaceuti can protect your principal portfolio during market swings. The stock standard deviation of daily returns for 90 days investing horizon is currently 1.97. The below-average Stock volatility is a good sign for longer-term investment options and for buy-and-hold investors.
Please see Risk vs Return Analysis.

Ironwood Stock Analysis 

 
Refresh
The Ironwood Pharmaceuti stock analysis report makes it easy to digest most publicly released information about Ironwood Pharmaceuti and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Ironwood Stock analysis module also helps to analyze the Ironwood Pharmaceuti price relationship with some important fundamental indicators such as market cap and management efficiency.

Ironwood Stock Analysis Notes

About 112.0% of the company shares are owned by institutional investors. The book value of Ironwood Pharmaceuti was currently reported as 3.55. The company has Price/Earnings To Growth (PEG) ratio of 0.13. Ironwood Pharmaceuti next dividend is scheduled to be issued on the 2nd of April 1970. The entity had a split on the 2nd of April 2019. Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal products. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts. Ironwood Pharmaceuti operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 232 people. To learn more about Ironwood Pharmaceuti call Mark Mallon at 617 621-7722 or check out www.ironwoodpharma.com.

Ironwood Pharmaceuti Quarterly Cost of Revenue

0.0Share

Ironwood Pharmaceuti Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Ironwood Pharmaceuti's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Ironwood Pharmaceuti or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Ironwood Pharmaceuti generated a negative expected return over the last 90 days
Ironwood Pharmaceuti has a strong financial position based on the latest SEC filings
Latest headline from MacroaxisInsider: Acquisition by Shetzline Michael of 29326 shares of Ironwood Pharmaceuti subject to Rule 16b-3

Ironwood Pharmaceuti Upcoming and Recent Events

Earnings reports are used by Ironwood Pharmaceuti to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Ironwood Pharmaceuti previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report16th of February 2022
Next Earnings Report5th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End16th of February 2022
Last Quarter Report30th of September 2021
Last Earning Announcement31st of December 2020

Ironwood Pharmaceuti SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Ironwood Pharmaceuti prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Ironwood Pharmaceuti investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Ironwood Pharmaceuti specific information freely available to individual and institutional investors to make a timely investment decision.
10th of January 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
1st of December 2021
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
4th of November 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
5th of August 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
22nd of July 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
24th of June 2021
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
7th of June 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
3rd of June 2021
Submission of Matters to a Vote of Security Holders
View

Ironwood Pharmaceuti Thematic Classifications

In addition to having Ironwood Pharmaceuti stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Obamacare Repeal IdeaObamacare Repeal
Large healthcare related equities associated with Obamacare

Ironwood Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 1.8 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Ironwood Pharmaceuti's market, we take the total number of its shares issued and multiply it by Ironwood Pharmaceuti's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Ironwood Profitablity

Ironwood Pharmaceuti's profitability indicators refer to fundamental financial ratios that showcase Ironwood Pharmaceuti's ability to generate income relative to its revenue or operating costs. If, let's say, Ironwood Pharmaceuti is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Ironwood Pharmaceuti's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Ironwood Pharmaceuti's profitability requires more research than a typical breakdown of Ironwood Pharmaceuti's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of 128.3 %, which can signify that it executes well on its competitive strategies and has good control over its expenditures. This is very large. Similarly, it shows Operating Margin (OM) of 58.45 %, which suggests for every 100 dollars of sales, it generated a net operating income of 0.58.
Last ReportedProjected for 2022
Return on Investment 31.86  34.37 
Return on Average Assets 0.26  0.28 
Return on Average Equity(9.59) (9.84) 
Return on Invested Capital 0.26  0.28 
Return on Sales 0.41  0.44 

Management Efficiency

The entity has return on total asset (ROA) of 19.21 % which means that it generated profit of $19.21 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 181.03 %, meaning that it created $181.03 on every $100 dollars invested by stockholders. Ironwood Pharmaceuti management efficiency ratios could be used to measure how well ironwood pharmaceuti manages its routine affairs as well as how well it operates its assets and liabilities. Ironwood Pharmaceuti Return on Average Assets are projected to increase slightly based on the last few years of reporting. The past year's Return on Average Assets were at 0.26. The current year Return on Invested Capital is expected to grow to 0.28, whereas Return on Average Equity is forecasted to decline to (9.84) . Ironwood Pharmaceuti Goodwill and Intangible Assets are projected to decrease significantly based on the last few years of reporting. The past year's Goodwill and Intangible Assets were at 706,500. The current year Return on Average Assets is expected to grow to 0.28, whereas Current Assets are forecasted to decline to about 481.4 M.
Last ReportedProjected for 2022
Book Value per Share 0.35  0.32 
Enterprise Value over EBIT 16.10  17.37 
Enterprise Value over EBITDA 15.97  17.23 
Price to Book Value 33.48  38.33 
Tangible Assets Book Value per Share 4.03  3.76 
Enterprise Value2.3 B2.3 B
Tangible Asset Value643.1 M567 M

Technical Drivers

As of the 26th of January, Ironwood Pharmaceuti retains the market risk adjusted performance of (0.27), and Risk Adjusted Performance of (0.09). Ironwood Pharmaceuti technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We are able to interpolate and break down nineteen technical drivers for Ironwood Pharmaceuti, which can be compared to its competitors. Please check out Ironwood Pharmaceuti standard deviation, maximum drawdown, as well as the relationship between the Maximum Drawdown and expected short fall to decide if Ironwood Pharmaceuti is priced fairly, providing market reflects its last-minute price of 11.09 per share. Given that Ironwood Pharmaceuti has jensen alpha of (0.19), we strongly advise you to confirm Ironwood Pharmaceuti's regular market performance to make sure the company can sustain itself at a future point.

Ironwood Pharmaceuti Price Movement Analysis

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Simple Moving Average indicator is calculated by adding the closing price of Ironwood Pharmaceuti for a given number of time periods and then dividing this total by the number of time periods. It is used to smooth out Ironwood Pharmaceuti short-term fluctuations and highlight longer-term trends or cycles. View also all equity analysis or get more info about simple moving average overlap studies indicator.

Ironwood Pharmaceuti Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ironwood Pharmaceuti insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ironwood Pharmaceuti's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Ironwood Pharmaceuti insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Shetzline Michael few days ago via Macroaxis 
Acquisition by Shetzline Michael of 29326 shares of Ironwood Pharmaceuti subject to Rule 16b-3
Thomas McCourt over a month ago via Macroaxis 
Sale by Thomas McCourt of 46327 shares of Ironwood Pharmaceuti
Rickard Jason over a month ago via Macroaxis 
Sale by Rickard Jason of 27000 shares of Ironwood Pharmaceuti
Catherine Moukheibir over a month ago via Macroaxis 
Acquisition by Catherine Moukheibir of 1541 shares of Ironwood Pharmaceuti subject to Rule 16b-3
Julie McHugh over a month ago via Macroaxis 
Sale by Julie McHugh of 10000 shares of Ironwood Pharmaceuti
Emany Sravan Kumar over a month ago via Macroaxis 
Acquisition by Emany Sravan Kumar of 85000 shares of Ironwood Pharmaceuti subject to Rule 16b-3
Silver Ronald over two months ago via Macroaxis 
Sale by Silver Ronald of 713 shares of Ironwood Pharmaceuti
Kelly MacDonald over three months ago via Macroaxis 
Exercise or conversion by Kelly MacDonald of 3561 shares of Ironwood Pharmaceuti subject to Rule 16b-3
Catherine Moukheibir over three months ago via Macroaxis 
Acquisition by Catherine Moukheibir of 1447 shares of Ironwood Pharmaceuti subject to Rule 16b-3
Silver Ronald over three months ago via Macroaxis 
Sale by Silver Ronald of 567 shares of Ironwood Pharmaceuti
John Minardo over three months ago via Macroaxis 
Acquisition by John Minardo of 79892 shares of Ironwood Pharmaceuti subject to Rule 16b-3
Silver Ronald over six months ago via Macroaxis 
Acquisition by Silver Ronald of 20000 shares of Ironwood Pharmaceuti subject to Rule 16b-3

Ironwood Pharmaceuti Predictive Daily Indicators

Ironwood Pharmaceuti intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Ironwood Pharmaceuti stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Ironwood Pharmaceuti Forecast Models

Ironwood Pharmaceuti time-series forecasting models is one of many Ironwood Pharmaceuti's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Ironwood Pharmaceuti's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Ironwood Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Ironwood Pharmaceuti stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Ironwood shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Ironwood Pharmaceuti. By using and applying Ironwood Stock analysis, traders can create a robust methodology for identifying Ironwood entry and exit points for their positions.
Last ReportedProjected for 2022
Operating Margin 33.03  35.64 
EBITDA Margin 0.42  0.45 
Gross Margin 1.14  1.12 
Profit Margin 0.31  0.34 
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal products. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts. Ironwood Pharmaceuti operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 232 people.

Current Ironwood Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Ironwood analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Ironwood analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
12.33Hold3Odds
Ironwood Pharmaceuti current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Ironwood analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Ironwood stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Ironwood Pharmaceuti, talking to its executives and customers, or listening to Ironwood conference calls.
Ironwood Analyst Advice Details

Ironwood Stock Analysis Indicators

Ironwood Pharmaceuti stock analysis indicators help investors evaluate how Ironwood Pharmaceuti stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Ironwood Pharmaceuti shares will generate the highest return on investment. By understating and applying Ironwood Pharmaceuti stock analysis, traders can identify Ironwood Pharmaceuti position entry and exit signals to maximize returns.
Quick Ratio4.64
Fifty Two Week Low8.78
Revenue Growth0.30%
Shares Short Prior Month20.96M
Average Daily Volume Last 10 Day2.69M
Average Daily Volume In Three Month2.19M
Earnings Growth61.90%
Shares Percent Shares Out11.20%
Earnings Quarterly Growth62.20%
Gross Margins86.52%
Short Percent Of Float20.95%
Forward Price Earnings8.20
Float Shares144.67M
Fifty Two Week High14.27
Enterprise Value To Ebitda7.50
Fifty Day Average11.53
Two Hundred Day Average12.20
Enterprise Value To Revenue4.39
Please see Risk vs Return Analysis. Note that the Ironwood Pharmaceuti information on this page should be used as a complementary analysis to other Ironwood Pharmaceuti's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Complementary Tools for Ironwood Stock analysis

When running Ironwood Pharmaceuti price analysis, check to measure Ironwood Pharmaceuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ironwood Pharmaceuti is operating at the current time. Most of Ironwood Pharmaceuti's value examination focuses on studying past and present price action to predict the probability of Ironwood Pharmaceuti's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Ironwood Pharmaceuti's price. Additionally, you may evaluate how the addition of Ironwood Pharmaceuti to your portfolios can decrease your overall portfolio volatility.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Is Ironwood Pharmaceuti's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ironwood Pharmaceuti. If investors know Ironwood will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ironwood Pharmaceuti listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Ironwood Pharmaceuti is measured differently than its book value, which is the value of Ironwood that is recorded on the company's balance sheet. Investors also form their own opinion of Ironwood Pharmaceuti's value that differs from its market value or its book value, called intrinsic value, which is Ironwood Pharmaceuti's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ironwood Pharmaceuti's market value can be influenced by many factors that don't directly affect Ironwood Pharmaceuti's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ironwood Pharmaceuti's value and its price as these two are different measures arrived at by different means. Investors typically determine Ironwood Pharmaceuti value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ironwood Pharmaceuti's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.